Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
REVENUES:    
Product revenue $ 3,492,881 $ 4,006,298
License and other revenue 35,708 35,708
Total Revenues 3,528,589 4,042,006
OPERATING EXPENSES    
Cost of product revenue (exclusive of amortization expense shown below) 9,405,179 12,242,748
Research and development 870,635 965,571
Plasma center operating expenses 654,486 1,833,774
Amortization of intangibles 211,235 211,235
Selling, general and administrative 5,595,470 5,321,181
TOTAL OPERATING EXPENSES 16,737,005 20,574,509
LOSS FROM OPERATIONS (13,208,416) (16,532,503)
OTHER INCOME (EXPENSE):    
Interest and other income 127,399 26,546
Interest expense (1,540,507) (1,323,152)
Loss on extinguishment of debt (9,962,495) 0
Gain on transfer of plasma center assets 11,527,421 0
Other (expense) income (11,357) 6,967
Other income (expense), net 140,461 (1,289,639)
NET LOSS $ (13,067,955) $ (17,822,142)
BASIC AND DILUTED LOSS PER COMMON SHARE $ (0.28) $ (0.39)
WEIGHTED AVERAGE SHARES OUTSTANDING, Basic and Diluted 46,353,068 45,317,042